Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

(2014) Tomáš Šimůnek et al.   Pharmacological Reports

Anthracyclines and Heart Failure

(2013) Douglas B. Sawyer   NEW ENGLAND JOURNAL OF MEDICINE

Oxidative Stress, Redox Signaling, and Metal Chelation in Anthracycline Cardiotoxicity and Pharmacological Cardioprotection

(2012) Martin Štěrba et al.   ANTIOXIDANTS & REDOX SIGNALING

Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: Novel iron chelators with selective antiproliferative action

(2012) Eliška Macková et al.   CHEMICO-BIOLOGICAL INTERACTIONS

DNA topoisomerase IIβ: A player in regulation of gene expression and cell differentiation

(2012) Anna Vávrová et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity

(2010) Anna Vávrová et al.   ARCHIVES OF TOXICOLOGY

Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury

(2010) Petra Bendova et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death

(2009) O Popelová et al.   BRITISH JOURNAL OF CANCER

Anthracycline Cardiotoxicity: From Bench to Bedside

(2008) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing

(2008) J. E. Deweese et al.   NUCLEIC ACIDS RESEARCH

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

(2008) Elke Martin et al.   TOXICOLOGY